Management of aneurysmal subarachnoid hemorrhage: State of the art and future perspectives

Surgical Neurology International

Volumn 8, Issue 11, 2017, Pages

  Grasso, Giovanni ^a   Alafaci, Concetta ^b   MacDonald, R Loch ^c,d  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Outcome; Subarachnoid hemorrhage; Treatment; Vasospasm

Indexed keywords

CLAZOSENTAN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN B RECEPTOR; ENDOTHELIN B1 RECEPTOR; ENDOTHELIN B2 RECEPTOR; GLIBENCLAMIDE; MAGNESIUM; NIMODIPINE; PRAVASTATIN; RECOMBINANT ERYTHROPOIETIN; SIMVASTATIN; TIRILAZAD; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN VASOSPASM; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS DISORDER; DIAGNOSTIC ACCURACY; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOVASCULAR COILING; ENDOVASCULAR SURGERY; HEADACHE; HUMAN; HYDROCEPHALUS; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPOTENSION; INTRACRANIAL PRESSURE; LUMBAR PUNCTURE; LUNG EDEMA; MICROSURGERY; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBITIS; PLEURA EFFUSION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEIZURE; SUBARACHNOID HEMORRHAGE; SURGICAL CLIPPING; SURGICAL TECHNIQUE; THROMBOSIS; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 85013489253     PISSN: None     EISSN: 21527806     Source Type: Journal    
DOI: 10.4103/2152-7806.198738     Document Type: Review

References (113)

1. The International Study of Unruptured Intracranial Aneurysms Investigators. Unruptured intracranial aneurysms - risk of rupture and risks of surgical intervention. International Study of Unruptured Intracranial Aneurysms Investigators. N Eng J Med 1998;339:1725-33.
2. Adamczyk P, He S, Amar AP, Mack WJ. Medical Management of Cerebral Vasospasm following Aneurysmal Subarachnoid Hemorrhage: A Review of Current and Emerging Therapeutic Interventions. Neurol Res Int 2013;2013:462491.
3. Alafaci C, Salpietro F, Grasso G, Sfacteria A, Passalacqua M, Morabito A, et al. Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage. Eur J Pharmacol 2000;406:219-25.
4. Arnaout OM, El Ahmadieh TY, Zammar SG, El Tecle NE, Hamade YJ, Aoun RJ, et al. Microsurgical Treatment of Previously Coiled Intracranial Aneurysms: Systematic Review of the Literature. World Neurosurg 2015;84:246-53.
5. Athar MK, Levine JM. Treatment options for cerebral vasospasm in aneurysmal subarachnoid hemorrhage. Neurotherapeutics 2012;9:37-43.
6. Barry C, Turner RJ, Corrigan F, Vink R. New therapeutic approaches to subarachnoid hemorrhage. Expert Opin Investig Drugs 2012;21:845-59.
7. Bederson JB, Connolly ES Jr, Batjer HH, Dacey RG, Dion JE, Diringer MN, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 2009;40:994-1025.
8. Biller J, Godersky JC, Adams HP Jr. Management of aneurysmal subarachnoid hemorrhage. Stroke 1988;19:1300-5.
9. Bonita R. Cigarette smoking, hypertension and the risk of subarachnoid hemorrhage: A population-based case-control study. Stroke 1986;17:831-5.
10. Bradford CM, Finfer S, O'Connor A, Yarad E, Firth R, McCallister R, et al. A randomised controlled trial of induced hypermagnesaemia following aneurysmal subarachnoid haemorrhage. Crit Care Resusc 2013;15:119-25.
11. Broderick JP, Brott T, Tomsick T, Huster G, Miller R. The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. N Eng J Med 1992;326:733-6.
12. Broderick JP, Brott TG, Duldner JE, Tomsick T, Leach A. Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. Stroke 1994;25:1342-7.
13. Buemi M, Grasso G, Corica F, Calapai G, Salpietro FM, Casuscelli T, et al. In vivo evidence that erythropoietin has a neuroprotective effect during subarachnoid hemorrhage. Eur J Pharmacol 2000;392:31-4.
14. Clozel M, Gray GA, Breu V, Loffler BM, Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992;186:867-73.
15. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: A guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke 2012;43:1711-37.
16. Dankbaar JW, Rijsdijk M, van der Schaaf IC, Velthuis BK, Wermer MJ, Rinkel GJ. Relationship between vasospasm, cerebral perfusion, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neuroradiology 2009;51:813-9.
17. Dhar R, Diringer M. Statins and anti-inflammatory therapies for subarachnoid hemorrhage. Curr Treatment Options Neurol 2012;14:164-74.
18. Diringer MN, Bleck TP, Claude Hemphill J 3rd, Menon D, Shutter L, Vespa P, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: Recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit care 2011;15:211-40.
19. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989;3:2007-18.
20. Gathier CS, Dankbaar JW, van der Jagt M, Verweij BH, Oldenbeuving AW, Rinkel GJ, et al. Effects of Induced Hypertension on Cerebral Perfusion in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage: A Randomized Clinical Trial. Stroke 2015;46:3277-81.
21. Grasso G. Erythropoiesis and neuroprotection: Two sides of the same coin? Lancet Neurol 2003;2:332.
22. Grasso G. Erythropoietin: A new paradigm for neuroprotection. J Neurosurg Anesthesiol 2006;18:91-2.
23. Grasso G. An overview of new pharmacological treatments for cerebrovascular dysfunction after experimental subarachnoid hemorrhage. Brain Res Brain Res Rev 2004;44:49-63.
24. Grasso G, Alafaci C, Passalacqua M, Meli F, Maugeri R, Giambartino F, et al. Aneurysm clipping following endovascular coil embolization: A report of two cases. Med Sci Monit 2009;15:CS63-6.
25. Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M, Sturiale A, et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci U S A 2002;99:5627-31.
26. Grasso G, Buemi M, Giambartino F. The role of erythropoietin in aneurysmal subarachnoid haemorrhage: From bench to bedside. Acta Neurochir Suppl 2015;120:75-80.
27. Grasso G, Passalacqua M, Sfacteria A, Conti A, Morabito A, Mazzullo G, et al. Does administration of recombinant human erythropoietin attenuate the increase of S-100 protein observed in cerebrospinal fluid after experimental subarachnoid hemorrhage? J Neurosurg 2002;96:565-70.
28. Grasso G, Sfacteria A. Erythropoietin and subarachnoid hemorrhage. J Neurosurg 2010;112(3):699-700.
29. Grasso G, Sfacteria A, Meli F, Passalacqua M, Fodale V, Buemi M, et al. The role of erythropoietin in neuroprotection: tTherapeutic perspectives. Drug News Perspect 2007;20:315-20.
30. Grasso G, Tomasello F. Erythropoietin for subarachnoid hemorrhage: Is there a reason for hope? World Neurosurg 2012;77:46-8.
31. Haley EC Jr, Kassell NF, Alves WM, Weir BK, Hansen CA. Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 1995;82:786-90.
32. Haley EC Jr, Kassell NF, Apperson-Hansen C, Maile MH, Alves WM. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in North America. J Neurosurg 1997;86:467-74.
33. Hall ED. Beneficial effects of the 21-aminosteroid U74006F in acute CNS trauma and hypovolemic shock. Acta Anaesthesiol Belg 1987;38:421-5.
34. Hop JW, Rinkel GJ, Algra A, van Gijn J. Case-fatality rates and functional outcome after subarachnoid hemorrhage: A systematic review. Stroke 1997;28:660-4.
35. Hop JW, Rinkel GJ, Algra A, van Gijn J. Initial loss of consciousness and risk of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke 1999;30:2268-71.
36. Hop JW, Rinkel GJ, Algra A, van Gijn J. Quality of life in patients and partners after aneurysmal subarachnoid hemorrhage. Stroke 1998;29:798-804.
37. Ide K, Yamakawa K, Nakagomi T, Sasaki T, Saito I, Kurihara H, et al. The role of endothelin in the pathogenesis of vasospasm following subarachnoid haemorrhage. Neurol Res 1989;11:101-4.
38. Investigators UJ, Morita A, Kirino T, Hashi K, Aoki N, Fukuhara S, et al. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Eng J Med 2012;366:2474-82.
39. Izzy S, Muehlschlegel S. Cerebral vasospasm after aneurysmal subarachnoid hemorrhage and traumatic brain injury. Curr Treat Options Neurol 2014;16:278.
40. Jayaraman MV, Haas RA, Do HM, Meyers PM. Should CT angiography be routinely used in patients suspected of having aneurysmal subarachnoid hemorrhage? No! Radiology 2010;254:314-5.
41. Jelkmann W. Biology of erythropoietin. Clin Investig 1994;72(6 Suppl):S3-10.
42. Johnston SC, Colford JM, Jr., Gress DR. Oral contraceptives and the risk of subarachnoid hemorrhage: A meta-analysis. Neurology 1998;51:411-8.
43. Juvela S. Alcohol and the prognosis of subarachnoid hemorrhage. Duodecim 1993;109:355-7.
44. Juvela S, Poussa K, Lehto H, Porras M. Natural history of unruptured intracranial aneurysms: A long-term follow-up study. Stroke 2013;44:2414-21.
45. Kallmes DF, Layton K, Marx WF, Tong F. Death by nondiagnosis: Why emergent CT angiography should not be done for patients with subarachnoid hemorrhage. AJNR Am J Neuroradiol 2007;28:1837-8.
46. Kassell NF, Haley EC Jr, Apperson-Hansen C, Alves WM. Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in Europe, Australia, and New Zealand. J Neurosurg 1996;84:221-8.
47. Kirkpatrick PJ, Turner CL, Smith C, Hutchinson PJ, Murray GD, Collaborators S. Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): A multicentre randomised phase 3 trial. Lancet Neurol 2014;13:666-75.
48. Knekt P, Reunanen A, Aho K, Heliovaara M, Rissanen A, Aromaa A, et al. Risk factors for subarachnoid hemorrhage in a longitudinal population study. J Clin Epidemiol 1991;44:933-9.
49. Koivisto T, Vanninen E, Vanninen R, Kuikka J, Hernesniemi J, Vapalahti M. Cerebral perfusion before and after endovascular or surgical treatment of acutely ruptured cerebral aneurysms: A 1-year prospective follow-up study. Neurosurgery 2002;51:312-25.
50. Koivisto T, Vanninen R, Hurskainen H, Saari T, Hernesniemi J, Vapalahti M. Outcomes of early endovascular versus surgical treatment of ruptured cerebral aneurysms. A prospective randomized study. Stroke 2000;31:2369-77.
51. Kunte H, Busch MA, Trostdorf K, Vollnberg B, Harms L, Mehta RI, et al. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. Ann Neurol 2012;72:799-806.
52. Lanzino G, Kassell NF. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America. J Neurosurg 1999;90:1018-24.
53. Lanzino G, Kassell NF, Germanson TP, Kongable GL, Truskowski LL, Torner JC, et al. Age and outcome after aneurysmal subarachnoid hemorrhage: Why do older patients fare worse? J Neurosurg 1996;85:410-8.
54. Leblanc R, Lozano AM. Graves' disease and subarachnoid hemorrhage: A possible familial association. Can J Neurol Sci 1987;14:638-41.
55. Leijenaar JF, Dorhout Mees SM, Algra A, van den Bergh WM, Rinkel GJ, Group M-IS. Effect of magnesium treatment and glucose levels on delayed cerebral ischemia in patients with subarachnoid hemorrhage: A substudy of the Magnesium in Aneurysmal Subarachnoid Haemorrhage trial (MASH-II). Int J Stroke 2015;10(Suppl A100):108-12.
56. Linn FH, Rinkel GJ, Algra A, van Gijn J. Headache characteristics in subarachnoid haemorrhage and benign thunderclap headache. J Neurol Neurosurg Psychiatry 1998;65:791-3.
57. Linn FH, Rinkel GJ, Algra A, van Gijn J. Incidence of subarachnoid hemorrhage: Role of region, year, and rate of computed tomography: A meta-analysis. Stroke 1996;27:625-9.
58. Linn FH, Wijdicks EF, van der Graaf Y, Weerdesteyn-van Vliet FA, Bartelds AI, van Gijn J. Prospective study of sentinel headache in aneurysmal subarachnoid haemorrhage. Lancet 1994;344:590-3.
59. Macdonald RL. Are statins to be STASHed in subarachnoid haemorrhage? Lancet Neurol 2014;13:639-41.
60. Macdonald RL. Clazosentan: An endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage. Expert Opin Investig Drugs 2008;17:1761-7.
61. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: A randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 2011;10:618-25.
62. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2). Acta Neurochir Suppl 2013;115:27-31.
63. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke 2012;43:1463-9.
64. McDougall CG, Spetzler RF, Zabramski JM, Partovi S, Hills NK, Nakaji P, et al. The Barrow Ruptured Aneurysm Trial. J Neurosurg 2012;116:135-44.
65. Menke J, Larsen J, Kallenberg K. Diagnosing cerebral aneurysms by computed tomographic angiography: Meta-analysis. Ann Neurol 2011;69:646-54.
66. Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: A randomised trial. Lancet 2002;360:1267-74.
67. Molyneux AJ, Birks J, Kerr RS. ISAT: End of the debate on coiling versus clipping? uthors' reply. Lancet 2015;385:2252.
68. Molyneux AJ, Kerr RS, Birks J, Ramzi N, Yarnold J, Sneade M, et al. Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): Long-term follow-up. Lancet Neurol 2009;8:427-33.
69. Molyneux AJ, Kerr RS, Yu LM, Clarke M, Sneade M, Yarnold JA, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: A randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 2005;366:809-17.
70. Moran CJ. Aneurysmal subarachnoid hemorrhage: DSA versus CT angiography - is the answer available? Radiology 2011;258:15-7.
71. Muroi C, Terzic A, Fortunati M, Yonekawa Y, Keller E. Magnesium sulfate in the management of patients with aneurysmal subarachnoid hemorrhage: A randomized, placebo-controlled, dose-adapted trial. Surg Neurol 2008;69:33-9.
72. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: A randomized controlled trial. JAMA 2011;305:1863-72.
73. Norrgard O, Angquist KA, Fodstad H, Forsell A, Lindberg M. Intracranial aneurysms and heredity. Neurosurgery 1987;20:236-9.
74. Petitti DB, Wingerd J. Use of oral contraceptives, cigarette smoking, and risk of subarachnoid haemorrhage. Lancet 1978;2:234-5.
75. Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989;298:636-42.
76. Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, et al. Oral nimodipine and cerebral ischaemia following subarachnoid haemorrhage. Br J Clin Pract 1990;44:66-7.
77. Pinto AN, Canhao P, Ferro JM. Seizures at the onset of subarachnoid haemorrhage. J Neurol 1996;243:161-4.
78. Pluta RM. Delayed cerebral vasospasm and nitric oxide: Review, new hypothesis, and proposed treatment. Pharmacol Ther 2005;105:23-56.
79. Rabinstein AA, Friedman JA, Nichols DA, Pichelmann MA, McClelland RL, Manno EM, et al. Predictors of outcome after endovascular treatment of cerebral vasospasm. AJNR Am J Neuroradiol 2004;25:1778-82.
80. Randall MD, Douglas SA, Hiley CR. Vascular activities of endothelin-1 and some alanyl substituted analogues in resistance beds of the rat. Br J Pharmacol 1989;98:685-99.
81. Reijneveld JC, Wermer M, Boonman Z, van Gijn J, Rinkel GJ. Acute confusional state as presenting feature in aneurysmal subarachnoid hemorrhage: Frequency and characteristics. J Neurol 2000;247:112-6.
82. Roos YB, de Haan RJ, Beenen LF, Groen RJ, Albrecht KW, Vermeulen M. Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: A prospective hospital based cohort study in the Netherlands. J Neurol Neurosurg Psychiatry 2000;68:337-41.
83. Schievink WI, Torres VE, Piepgras DG, Wiebers DO. Saccular intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1992;3:88-95.
84. Sheth KN, Elm JJ, Molyneaux BJ, Hinson H, Beslow LA, Sze GK, et al. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2016;15:1160-9.
85. Simard JM, Chen M, Tarasov KV, Bhatta S, Ivanova S, Melnitchenko L, et al. Newly expressed SUR1-regulated NC (Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nature Med 2006;12:433-40.
86. Simard JM, Geng Z, Woo SK, Ivanova S, Tosun C, Melnichenko L, et al. Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2009;29:317-30.
87. Simard JM, Woo SK, Schwartzbauer GT, Gerzanich V. Sulfonylurea receptor 1 in central nervous system injury: A focused review. J Cereb Blood Flow Metab 2012;32:1699-717.
88. Spetzler RF, McDougall CG, Albuquerque FC, Zabramski JM, Hills NK, Partovi S, et al. The Barrow Ruptured Aneurysm Trial: 3-year results. J Neurosurg 2013;119:146-57.
89. Spetzler RF, McDougall CG, Zabramski JM, Albuquerque FC, Hills NK, Russin JJ, et al. The Barrow Ruptured Aneurysm Trial: 6-year results. J Neurosurg 2015;123:609-17.
90. Springborg JB, Moller C, Gideon P, Jorgensen OS, Juhler M, Olsen NV. Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: A double blind randomised clinical trial. Acta Neurochir 2007;149:1089-101.
91. Taccone FS. Vasodilation and neuroprotection: The magnesium saga in subarachnoid hemorrhage. Crit Care Med 2010;38:1382-4.
92. Takizawa T, Tada T, Kitazawa K, Tanaka Y, Hongo K, Kameko M, et al. Inflammatory cytokine cascade released by leukocytes in cerebrospinal fluid after subarachnoid hemorrhage. Neurolog Res 2001;23:724-30.
93. Tettenborn D, Dycka J. Prevention and treatment of delayed ischemic dysfunction in patients with aneurysmal subarachnoid hemorrhage. Stroke 1990;21(12 Suppl):IV85-9.
94. Teunissen LL, Rinkel GJ, Algra A, van Gijn J. Risk factors for subarachnoid hemorrhage: A systematic review. Stroke 1996;27:544-9.
95. Tolias CM, Choksey MS. Will increased awareness among physicians of the significance of sudden agonizing headache affect the outcome of subarachnoid hemorrhage? Coventry and Warwickshire Study: Audit of subarachnoid hemorrhage (establishing historical controls), hypothesis, campaign layout, and cost estimation. Stroke 1996;27:807-12.
96. Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, et al. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: A Phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg 2009;111:171-80.
97. van den Bergh WM, Algra A, van der Sprenkel JW, Tulleken CA, Rinkel GJ. Hypomagnesemia after aneurysmal subarachnoid hemorrhage. Neurosurgery 2003;52:276-81.
98. van den Bergh WM, Algra A, van Kooten F, Dirven CM, van Gijn J, Vermeulen M, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: A randomized controlled trial. Stroke 2005;36:1011-5.
99. van den Bergh WM, Dijkhuizen RM, Rinkel GJ. Potentials of magnesium treatment in subarachnoid haemorrhage. Magnes Res 2004;17:301-13.
100. van der Wee N, Rinkel GJ, Hasan D, van Gijn J. Detection of subarachnoid haemorrhage on early CT: Is lumbar puncture still needed after a negative scan? J Neurol Neurosurg Psychiatry 1995;58:357-9.
101. Vanninen R, Koivisto T, Saari T, Hernesniemi J, Vapalahti M. Ruptured intracranial aneurysms: Acute endovascular treatment with electrolytically detachable coils - a prospective randomized study. Radiology 1999;211:325-36.
102. Vergouwen MD, Meijers JC, Geskus RB, Coert BA, Horn J, Stroes ES, et al. Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: A double-blind, placebo-controlled randomized trial. J Cereb Blood Flow Metab 2009;29:1444-53.
103. Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: Proposal of a multidisciplinary research group. Stroke 2010;41:2391-5.
104. Veyna RS, Seyfried D, Burke DG, Zimmerman C, Mlynarek M, Nichols V, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg 2002;96:510-4.
105. Wardlaw JM, White PM. The detection and management of unruptured intracranial aneurysms. Brain 2000;123(Pt 2):205-21.
106. Westerlaan HE, van Dijk JM, Jansen-van der Weide MC, de Groot JC, Groen RJ, Mooij JJ, et al. Intracranial aneurysms in patients with subarachnoid hemorrhage: CT angiography as a primary examination tool for diagnosis - systematic review and meta-analysis. Radiology 2011;258:134-45.
107. Westermaier T, Stetter C, Vince GH, Pham M, Tejon JP, Eriskat J, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: A randomized, placebo-controlled, clinical study. Crit Care Med 2010;38:1284-90.
108. Wiebers DO, Whisnant JP, Huston J 3rd, Meissner I, Brown RD Jr, Piepgras DG, et al. Unruptured intracranial aneurysms: Natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003;362:103-10.
109. Winn HR, Jane JA, Sr., Taylor J, Kaiser D, Britz GW. Prevalence of asymptomatic incidental aneurysms: Review of 4568 arteriograms. J Neurosurg 2002;96:43-9.
110. Wong GK, Boet R, Poon WS, Chan MT, Gin T, Ng SC, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage: An updated systemic review and meta-analysis. Crit Care 2011;15:R52.
111. Wong GK, Poon WS. Clazosentan for patients with subarachnoid haemorrhage: Lessons learned. Lancet Neurol 2011;10:871.
112. Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): A randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke 2010;41:921-6.
113. Zuccarello M, Boccaletti R, Romano A, Rapoport RM. Endothelin B receptor antagonists attenuate subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 1998;29:1924-9.